Business of Biotech Shorts

  1. Ep. 252, Chapter 2: Commercializing RNAi with Tolga Tanguler 7/8/2025

    Tanguler explains how the unique opportunities presented by commercial RNAi drugs can overcome physician skepticism and poor patient adherence. RNAi therapies like Alnylam Pharmaceuticals’ Leqvio (a quarterly subcutaneous injection for hypercholesterolemia) and the experimental Zilebesiran (a semi-annual injection for hypertension) offer high adherence rates (90-95%) due to their infrequent, convenient administration. Additionally, RNAi drugs fit within existing reimbursement structures.

  2. Ep. 252, Chapter 1: Tolga Tanguler & Alnylam 7/8/2025

    Chief Editor of Life Science Leader and Host of The Business of Biotech, Ben Comer, and Tolga Tanguler, EVP and CCO and at Alnylam Pharmaceuticals, discuss Tanguler’s career path from Merck and Pfizer to Alnylam Pharmaceuticals, an innovator in the RNA interference (RNAi) therapeutic space. Tanguler details how early work in a stigmatic disease area, followed by his son’s childhood leukemia diagnosis, shaped his approach to science and medicine.

  3. Involve CMC And Formulations Experts Early In Process Development 6/2/2025

    In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists talk about the cross-functional importance of formulations and CMC leads in process development.

  4. Addressing Manufacturability And Scalability Challenges In Multispecifics Purification 6/2/2025

    In this final segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists answer some remaining audience questions relating to viral inactivation, affinity resins, precipitation steps in purification, and downstream scalability challenges.

  5. Characterizing Product- And Process-Related Impurities In Multispecifics 6/2/2025

    In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists Mark Fitchmun and Dr. Jian Ren examine the types of common impurities manufacturers encounter in multispecific purification and explain the differences between product-related impurities and process-related impurities.

  6. Purification Strategies For Multispecifics 6/2/2025

    In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists Mark Fitchmun and Dr. Jian Ren debate the use of affinity resins compared to ion exchange and multimodal chromatography methods.

  7. Strategies For Viral Inactivation And Filtration In Multispecifics 6/2/2025

    In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists cover molecule sensitivity to low pH and the use of detergent-based viral inactivation, as well as evaluating the suitability of platform viral filters.

  8. Analytics Are The Eyes Of Process Development 6/2/2025

    In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” panelists Mark Fitchmun and Dr. Jian Ren emphasize the importance of good analytics for your purification strategy.

  9. Clinical Trial Strategy And ADC Dev Partnership 4/29/2025

    As the Bioprocess Online Live panel discussion Accelerating ADC Process Development wraps up, expert panelists Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) address audience questions on AI-driven stratification of patients and biomarkers in clinical patient enrollment and IP strategies and collaboration.

  10. ADC Heterogeneity, Site-Specific Conjugation 4/29/2025

    This busy segment of the Bioprocess Online Live panel discussion Accelerating ADC Process Development finds Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) addressing DAR variability and lipophilic toxicity, homogeneity, computational tools to address molecular design and ADC behavior, and revisiting strategic considerations in CDMO selection before addressing a second live poll of our audience.